|
|
Résultats pour
brevets
1.
|
NOVEL AMINOGUANIDINES AS MELANOCORTIN RECEPTOR LIGANDS.
| Numéro d'application |
GB2007004793 |
| Numéro de publication |
2008/071980 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2007-12-13 |
| Date de publication |
2008-06-19 |
| Propriétaire |
- ACURE PHARMA AB (Suède)
- PETT, Christopher, Phineas (Royaume‑Uni)
|
| Inventeur(s) |
- Lundstedt, Torbjörn
- Seifert, Elisabeth
- Lek, Per
- Boman, Arne
|
Abrégé
There are described compounds of general formula (I) and isomeric forms thereof wherein n is 0,1,2 or 3, saturated or unsaturated; most preferably at least one of R1 to R5 represents halogen; at least one of R1, R2, R3, R4 and R5 is selected from -S-R or -COOR, or two or more Of R1-R5 comprise a linking group such as -S-(CH2)mS-, where m is 1, 2 or 3 and R is selected from alkyl having 1 to 5 carbon atoms, cycloalkyl having 3-6 carbon atoms, hydroxy, and aryl having 6 to 10 carbon atoms, such groups being optionally substituted, and when R1 is selected from -S-R, then at least one of R2, R3 and R5 is most preferably selected from halogen; and R1, R2, R3, R4 and R5 are otherwise the same or different and are selected from hydrogen, halogen, alkyl having 1 to 5 carbon atoms, electron donor groups such as alkoxy having 1-5 carbon atoms or hydroxy, electron acceptor groups selected from cyano, nitro, trifluoroalkyl or amide; alkylamino, benzoyloxy, nitroxy, phenyl or sulpho; and pharmacologically acceptable salts thereof. Compounds described have activity on the melanocortin receptors and have application in the treatment of a wide range of inflammatory, arthritic or central nerve regeneration conditions.
Classes IPC ?
- C07C 281/18 - Composés contenant l'un des groupes p. ex. aminoguanidine l'autre atome d'azote étant lié de plus par une liaison double à un atome de carbone, p. ex. guanylhydrazones
- C07D 339/08 - Cycles à six chaînons
- A61K 31/155 - Amidines (), p. ex. guanidine (H2N-C(=NH)-NH2), isourée (HN=C(OH)NH2), isothiourée (HN=C(SH)-NH2)
- A61K 31/385 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant plusieurs atomes de soufre dans le même cycle
- A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
|
2.
|
USE OF A COMPOUND AS VEGF INHIBITOR
| Numéro d'application |
EP2007009767 |
| Numéro de publication |
2008/061647 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2007-11-12 |
| Date de publication |
2008-05-29 |
| Propriétaire |
ACURE PHARMA AB (Suède)
|
| Inventeur(s) |
- Lundstedt, Torbjörn
- Ekström, Gunilla
|
Abrégé
There is disclosed the use of N-(2-chloro-3,4-dimethoxybenzylideneamino)guanidine or a pharmacologically acceptable salt thereof as an agent for use in the inhibition of Vascular Endothelial Growth Factor (VEGF). Such an agent is likely to be of application in the treatment or prevention of undesired blood vessel formation during tumour growth and/or in inflammatory conditions.
Classes IPC ?
- A61K 31/155 - Amidines (), p. ex. guanidine (H2N-C(=NH)-NH2), isourée (HN=C(OH)NH2), isothiourée (HN=C(SH)-NH2)
- A61P 35/00 - Agents anticancéreux
- A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
|
3.
|
NOVEL AMIDES ACTING ON THE ADENOSINE RECEPTORS
| Numéro d'application |
EP2007009721 |
| Numéro de publication |
2008/058679 |
| Statut |
Délivré - en vigueur |
| Date de dépôt |
2007-11-09 |
| Date de publication |
2008-05-22 |
| Propriétaire |
ACURE PHARMA AB (Suède)
|
| Inventeur(s) |
- Lundstedt, Torbjörn
- Seifert, Elisabeth
- Lek, Per
- Boman, Arne
|
Abrégé
There are described compounds of formula (I) in which R3 to R8 are independently selected from hydrogen, halogen, trihaloalkyl, alkyl having 1, 2, 3, 4 or 5 carbon atoms, electron donor groups selected from alkoxy having 1, 2, 3, 4 or 5 carbon atoms, trihaloalkoxy, hydroxy or amino, electron acceptor groups selected from cyano, sulphonic, nitro, or amide; R1 is an optionally substituted phenyl, benzyl or cyclohexyl group; R2 is selected from amino, substituted amino or guanidino groups, Z is a saturated or unsaturated C1-5 hydrocarbon chain, and salts thereof. A process for their preparation and compositions containing them are also described. The compounds are either agonists or antagonists of a specific adenosine receptor or a number of adenosine receptors and have usefulness for the treatment of inflammation, arthritic conditions, rheumatoid arthritis, osteoarthritis, mental disorders, or for inducing central nerve regeneration.
Classes IPC ?
- C07K 5/023 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale dans laquelle au moins un bêta-amino-acide est impliqué
- C07K 5/027 - Peptides ayant jusqu'à quatre amino-acides dans une séquence entièrement déterminéeLeurs dérivés contenant au moins une liaison peptidique anormale dans laquelle au moins un gamma-amino-acide est impliqué, p. ex. statine
- A61K 38/05 - Dipeptides
- A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
|
|